Diabetes a obezita - Issue 44/2022
74
91
New therapeutic indications for SGLT2 inhibitors
Zbynek Schroner
95
Effect of intensive lifestyle modification in patients with obesity (even extreme obesity) on cardiometabolic parameters
Adela Penesová, Jana Babjaková, Viktor Bielik, Žofia Rádiková, Libuša Kubáňová
103
Practical experience with empagliflozin in the light of new possibilities: case reports
Iveta Marková, Lenka Godál, Eva Horská, Zbynek Schroner
109
MAFLD screening in real practice in Slovakia: the SIRIUS study
Mária Szántová, Tomáš Koller, Marek Rác, Svetlana Adamcová-Selčanová, Xénia Faktorová, Martina Jakabovičová, Zuzana Urkovičová, Viliam Mojto, Peter Jarčuška, Martin Janíčko, Ubomír Skladaný
129
133
Jarná diabetologická konferencia: správa z odborného podujatia
Jozef Polko, Zbynek Schroner
138
Zpráva z kongresu Americké diabetologické asociace 2022
Martin Haluzík
142
Sumár z 58. výročného kongresu Európskej asociácie pre štúdium diabetu
Peter Novodvorský
Diabetes a obezita
2022 Issue 44
Most read in this issue
- Finerenone – a new option to reduce the risk of progression of renal and cardiovascular damage in patients with chronic kidney disease and type 2 diabetes mellitus
- MAFLD screening in real practice in Slovakia: the SIRIUS study
- New therapeutic indications for SGLT2 inhibitors
- Effect of intensive lifestyle modification in patients with obesity (even extreme obesity) on cardiometabolic parameters